David T Levy1, Zhe Yuan1, Yameng Li1, Anthony J Alberg2, K Michael Cummings3,4. 1. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. 2. Department of Epidemiology and Biostatistics, University of South Carolina Arnold School of Public Health, Columbia, SC, USA. 3. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA. 4. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Abstract
BACKGROUND AND AIMS: The long-term population health impact of nicotine vaping products (NVPs) use among smokers is unknown, and subject to a range of plausible assumptions about the use and health consequences of NVPs. While NVPs use may substitute for cigarette smoking and thereby aid in quitting cigarette use, it is also possible that smokers who would have otherwise quit would instead delay quitting cigarettes. We aimed to develop a cohort-specific simulation model of the impact of NVPs on smoking cessation by adult smokers and resulting premature deaths (PD) and life years lost (LYL). DESIGN: A cohort-specific simulation model of the impact of NVPs on smoking cessation by adult smokers and resulting premature deaths (PD) and life years lost (LYL) was developed by gender for two birth cohorts, aged 30 and 50 years in 2012. Extensive sensitivity analyses were conducted. SETTING: United States. PARTICIPANTS: Smokers in two birth cohorts, aged 30 and 50 years in 2012. MEASUREMENTS: Data were from the 1965-2012 National Health Interview Surveys and the 2014/15 Tobacco Use Supplement of the Current Population Survey. The model incorporated a range of plausible assumptions from published literature about transition rates from regular smoking to exclusive NVP and dual use, from dual use to exclusive NVP use and from exclusive NVP use to no use. FINDINGS: Compared with the no-NVP scenario, the male (female) model projected 17.8% (19.3%) fewer PDs and 22.9% (26.6%) fewer LYL for the 1982 cohort and 5.4% (7.3%) fewer PDs and 7.9% (11.4%) fewer LYL for the 1962 cohort. These gains were sensitive to NVP use over time, age of initial NVP use, transitions from smoking to dual, exclusive NVP and no use and relative NVP mortality risks. CONCLUSIONS: Nicotine vaping product (NVP) use in the United States is projected to have a net positive impact on population health over a wide range of plausible levels of NVP use, transitions to dual, exclusive NVP and no use and NVP risks. However, net impact is sensitive to parameter estimates.
BACKGROUND AND AIMS: The long-term population health impact of nicotine vaping products (NVPs) use among smokers is unknown, and subject to a range of plausible assumptions about the use and health consequences of NVPs. While NVPs use may substitute for cigarette smoking and thereby aid in quitting cigarette use, it is also possible that smokers who would have otherwise quit would instead delay quitting cigarettes. We aimed to develop a cohort-specific simulation model of the impact of NVPs on smoking cessation by adult smokers and resulting premature deaths (PD) and life years lost (LYL). DESIGN: A cohort-specific simulation model of the impact of NVPs on smoking cessation by adult smokers and resulting premature deaths (PD) and life years lost (LYL) was developed by gender for two birth cohorts, aged 30 and 50 years in 2012. Extensive sensitivity analyses were conducted. SETTING: United States. PARTICIPANTS: Smokers in two birth cohorts, aged 30 and 50 years in 2012. MEASUREMENTS: Data were from the 1965-2012 National Health Interview Surveys and the 2014/15 Tobacco Use Supplement of the Current Population Survey. The model incorporated a range of plausible assumptions from published literature about transition rates from regular smoking to exclusive NVP and dual use, from dual use to exclusive NVP use and from exclusive NVP use to no use. FINDINGS: Compared with the no-NVP scenario, the male (female) model projected 17.8% (19.3%) fewer PDs and 22.9% (26.6%) fewer LYL for the 1982 cohort and 5.4% (7.3%) fewer PDs and 7.9% (11.4%) fewer LYL for the 1962 cohort. These gains were sensitive to NVP use over time, age of initial NVP use, transitions from smoking to dual, exclusive NVP and no use and relative NVPmortality risks. CONCLUSIONS:Nicotine vaping product (NVP) use in the United States is projected to have a net positive impact on population health over a wide range of plausible levels of NVP use, transitions to dual, exclusive NVP and no use and NVP risks. However, net impact is sensitive to parameter estimates.
Authors: Krishna P Reddy; Alexander J B Bulteel; Douglas E Levy; Pamela Torola; Emily P Hyle; Taige Hou; Benjamin Osher; Liyang Yu; Fatma M Shebl; A David Paltiel; Kenneth A Freedberg; Milton C Weinstein; Nancy A Rigotti; Rochelle P Walensky Journal: BMJ Open Date: 2020-05-12 Impact factor: 2.692
Authors: Nick Wilson; Jennifer A Summers; Driss Ait Ouakrim; Janet Hoek; Richard Edwards; Tony Blakely Journal: BMC Public Health Date: 2021-11-08 Impact factor: 4.135
Authors: David T Levy; Luz María Sánchez-Romero; Nargiz Travis; Zhe Yuan; Yameng Li; Sarah Skolnick; Jihyoun Jeon; Jamie Tam; Rafael Meza Journal: Int J Environ Res Public Health Date: 2021-05-03 Impact factor: 4.614